Targeting Aberrant Histone Posttranscription Modification Machinery in Esophageal Squamous Cell Carcinoma: Current Findings and Challenges

Gang Ma; Tongyang Gong; Zhihua Liu

doi:10.34133/2022/9814607

Targeting Aberrant Histone Posttranscription Modification Machinery in Esophageal Squamous Cell Carcinoma: Current Findings and Challenges

Research (Wash D C). 2022 Aug 17:2022:9814607. doi: 10.34133/2022/9814607. eCollection 2022.

Authors

Gang Ma¹, Tongyang Gong², Zhihua Liu²

Affiliations

¹ Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
² State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Abstract

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy, but the survival rates of patients with ESCC have not improved as yet largely because the available targeted therapies are limited. Histone posttranscription modification (PTM) is a critical epigenetic regulation. Several deregulations in histone PTM machinery have been identified to promote malignant phenotypes of ESCC, providing druggable targets in treating ESCC. Hereby, we briefly describe current progress and challenges ahead in this field.